Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -16.60% lower on its value in year-to-date trading and has touched a low of $35.95 and a high of $54.44 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $41.02 in the last trading session, with the day’s gains setting it 1.17%.
Currently trading at $42.19, the stock is -9.95% and -11.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.23 million and changing 2.85% at the moment leaves the stock -7.97% off its SMA200. IONS registered -2.22% loss for a year compared to 6-month gain of 0.02%.
The stock witnessed a -9.95% loss in the last 1 month and extending the period to 3 months gives it a 2.60%, and is -10.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.51% over the week and 3.34% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 927 employees, a market worth around $6.65B and $813.95M in sales. Profit margin for the company is -44.90%. Distance from 52-week low is 17.36% and -22.51% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.64%).
The EPS is expected to shrink by -38.56% this year.
Ionis Pharmaceuticals Inc (IONS) Top Institutional Holders
508.0 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 96.56% of the company’s shares. The shares outstanding are 157.71M, and float is at 144.60M with Short Float at 7.03%. Institutions hold 95.81% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $1.04 billion. The investor’s holdings represent 15.044% of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6848% and valued at over $602.41 million, while BLACKROCK INC. holds 7.0916 of the shares totaling 10.32 million with a market value of $491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by Geary Richard S, the company’s EVP, Chief Development Officer. SEC filings show that Geary Richard S sold 331 shares of the company’s common stock on Aug 29 ’24 at a price of $49.63 per share for a total of $16428.0. Following the sale, the insider now owns 84823.0 shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 28 ’24 that Geary Richard S (EVP, Chief Development Officer) sold a total of 320 shares of the company’s common stock. The trade occurred on Aug 28 ’24 and was made at $49.16 per share for $15731.0. Following the transaction, the insider now directly holds 85154.0 shares of the IONS stock.
Still, SEC filings show that on Aug 05 ’24, Geary Richard S (EVP, Chief Development Officer) disposed off 2,430 shares at an average price of $48.00 for $0.12 million. The insider now directly holds 85,508 shares of Ionis Pharmaceuticals Inc (IONS).
